Remarks on the neoadjuvant therapy specific analysis
Neoadjuvant therapy for breast cancer
... The multivariate analysis confirmed that the probability of receiving NT increased 3.8 times in stage III (compared to stage II). The same value was observed in another study only for stage IIIA 13 ; in stages ...
6
Analysis of Presentation, Management and outcome following Neoadjuvant Therapy in Carcinoma Rectum.
... 11 Unresectable group – ends in leaving tumor within the pelvis,after chemoradiotherapy turn resectable. Residual microscopic disease can persist after surgery at resection margins, within lymph nodes, or in distant ...
91
Neoadjuvant therapy before surgical treatment
... 3. Brachytherapy High-dose-rate intraluminal brachytherapy (HDRBT) is highly conformal; the rapid fall-off in dose allows a high dose of radi- ation to be delivered at the mucosal surface of the rectum over- lying the ...
15
Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis
... square) statistic using a planned cut-off for significance of p < 0.05. Potential sources of heterogeneity were postu- lated a priori and included study quality assessed with the Jadad scale [20] (>2 versus ≤2), ...
17
Neoadjuvant and Adjuvant Hormone Therapy: How and When?
... deprivation therapy to radiotherapy Although a survival benefit of adjuvant ADT to RT over RT alone has been shown in patients with high- risk localised and locally advanced PCa, some questions ...pooled ...
5
Neoadjuvant Breast Cancer Therapy and Drug Development
... pooled analysis was the first large analysis in which primary source data had been used to examine the association between pCR and EFS and OS at a trial ...pooled analysis could not establish a ...
7
Neoadjuvant Therapy of Pancreatic Cancer: The Emerging Paradigm?
... CURRENT NEOADJUVANT THERAPIES To date, well-designed, randomized studies that directly com- pare neoadjuvant therapy followed by resection to upfront re- section, or comparison of the ...
9
Neoadjuvant or Adjuvant Therapy for Resectable Gastric Cancer
... A preoperative radiotherapy approach seems to provide a superior outcome with respect to 3-year and 5-year OS. However, this treatment has not been taken up in the North American oncology community. There are four main ...
70
Predicting and modifying response to neoadjuvant therapy in colorectal cancer
... to neoadjuvant treatment, again there was heterogeneity between ...the specific agents ...received neoadjuvant therapy it is possible that only chemo-resistant cells remained for sampling and ...
394
The contribution of targeted therapy to the neoadjuvant chemoradiation of rectal cancer.
... 5.1.2. New biomarkers and pharmacogenomic studies A plethora of potential histopathological, imaging and molecular predictive biomarkers have been evaluated by using single or multimarker assays and whole-genome anal- ...
23
Neoadjuvant therapy versus upfront surgery for potentially resectable pancreatic cancer : a Markov decision analysis
... Unlike previous Markov decision-analysis, weighted survival times were based on the Gillen et al. formulae as evidence has shown that unbiased pooled estimates of median survival times cannot be achieved by ...
20
Recent advances in systemic therapy Advances in neoadjuvant (primary) systemic therapy with cytotoxic agents
... 733 women with primary breast cancer. Pegfilgrastim was used as a secondary preventive after febrile neutropenia in the standard arm of the study or, in exceptional cases, after severe febrile neutropenia necessitating ...
7
Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy
... starting neoadjuvant treatment for locally advanced esophageal cancer never made it to esophagectomy, more than half of them for oncological reasons, but also ...
9
Targeted neoadjuvant therapy in the HER-2-positive breast cancer patients: a systematic review and meta-analysis
... The neoadjuvant (TECHNO) study reported that chemotherapy plus trastuzumab resulted in sig- nificantly higher survival rate in PCR group compared to that of non-PCR ...
12
Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy
... before therapy, present in about 24 % of the patients and reflecting the heteroge- neous CTC population, were eliminated by the given ...dicating therapy-resistant tumor cell ...after therapy did not ...
15
Predictive factors for response to neoadjuvant therapy in patients with oesophageal cancer
... Extended data on proliferation indices expressed as a percentage of MIB-1 positive tumour cells are presented now using multivariate analysis for statistics. To our knowl- edge this is the first study which ...
7
Effect of neoadjuvant therapy on tumor size reduction in breast cancer
... Statistical analysis: Statistical analysis was produced using an analytical tool Minitab ...statistical analysis was done for Demographic data, clinical staging, the presence of recurrence, treatment ...
5
Neoadjuvant hormonal therapy is a feasible option in laparoscopic radical prostatectomy
... Methods: From January 2004 to September 2009, 342 patients undergoing LRP were analyzed, specifically comparing 72 patients who received NHT to 270 who did not. All patients were in clinical stage T2 and nerve sparing ...
6
Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial
... Since particular microRNA (miRNA) signatures are as- sociated with BC subtypes and aggressiveness, as well as patient response to drug therapy and clinical outcome [2, 3], they open up new approaches for the ...
16
Xenobiotic transporter expression in breast cancer patients treated with neoadjuvant systemic therapy: implications for therapy
... single specific chemotherapeutic agent thereby selecting for resistance; the resultant resistant cell lines typically show a MDR phenotype against multiple unrelated drugs, with deregulation of ABC transporters ...
218